Research Article
A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
Table 1
Baseline demographic and clinical characteristics.
| | Baricitinib + dexamethasone + remdesivir n = 81 | Dexamethasone + remdesivir n = 110 | Odds ratio | value | 95% CI |
| BMI | | | 1.01 | 0.55 | 0.97–1.05 | Mean | 31.87 ± 0.78 | 30.36 ± 0.90 | | | | Median | 31.7 | 29.75 | | | |
| Age | | | 0.99 | 0.38 | 0.97–1.01 | Mean | 61.67 ± 1.76 | 64.68 ± 1.67 | | | | Median | 62 | 63 | | | |
| Gender (%) | | | 0.56 | 0.07 | 0.29–1.05 | Male | 50 (61.73) | 82 (74.55) | | | | Female | 31 (38.27) | 28 (25.45) | | | |
| Race (%) | | | 0.95 | 0.37 | 0.86–1.05 | American Indian or Alaskan native | 1 (1.23) | 1 (0.91) | | | | Asian | 3 (3.7) | 1 (0.91) | | | | Asian Indian | 7 (8.64) | 5 (4.55) | | | | Black | 14 (17.28) | 23 (20.91) | | | | Filipino | 2 (2.47) | 3 (2.73) | | | | Samoan | 0 (0) | 2 (1.82) | | | | Other Pacific islander | 2 (2.47) | 1 (0.91) | | | | White | 40 (49.38) | 63 (57.27) | | | | Unknown | 2 (2.47) | 0 (0) | | | | Patient declined | 10 (12.35) | 11 (10) | | | |
| Ordinal score (%) | 4 = hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise | 3 (3.7) | 10 (9.09) | | | | 5 = hospitalized, requiring supplemental oxygen | 25 (30.86) | 48 (43.64) | | | | 6 = hospitalized, on noninvasive ventilation or high-flow oxygen devices | 53 (65.43) | 52 (47.27) | | | |
| Pre-existing comorbidities (%) | Asthma | 6 (7.41) | 6 (5.45) | 1.52 | 0.5 | 0.45–5.10 | Congestive heart failure | 7 (8.64) | 14 (12.73) | 0.86 | 0.79 | 0.29–2.53 | Chronic kidney disease | 9 (11.11) | 24 (21.81) | 0.46 | 0.1 | 0.18–1.16 | Chronic obstructive pulmonary disease | 7 (8.64) | 9 (8.18) | 1.2 | 0.74 | 0.41–3.53 | Diabetes | 36 (44.44) | 42 (38.18) | 1.53 | 0.19 | 0.81–2.87 | Hyperlipidemia | 41 (50.61) | 47 (42.73) | 1.62 | 0.16 | 0.83–3.16 | Hypertension | 44 (54.32) | 68 (61.82) | 0.63 | 0.19 | 0.32–1.25 | Hypothyroidism | 11 (13.58) | 11 (10) | 1.62 | 0.31 | 0.64–4.11 | Tocilizumab (%) | 17 (20.99) | 28 (25.45) | 0.93 | 0.86 | 0.43–2.03 |
|
|